Production of Sm-153 With Very High Speciﬁc Activity for Targeted Radionuclide Therapy

Michiel Van de Voorde; Charlotte Duchemin; Heinke Reinhard; Laura Lambert; Eric Chevallay; Thomas Schneider; Miranda Van Stenis; Thomas Elias Cocolios; Thomas Cardinaels; Bernard Ponsard; Maarten Ooms; Thierry Stora; Andrew Burgoyne

doi:10.3389/fmed.2021.675221

Production of Sm-153 With Very High Speciﬁc Activity for Targeted Radionuclide Therapy

Michiel Van de Voorde
, Charlotte Duchemin
, Heinke Reinhard
, Laura Lambert
, Eric Chevallay
, Thomas Schneider
, Miranda Van Stenis
, Thomas Elias Cocolios
, Thomas Cardinaels
, Bernard Ponsard
, Maarten Ooms
, Thierry Stora
, Andrew Burgoyne

Research output › peer-review

Abstract

Targeted radionuclide therapy (TRNT) has proven to be successful in oncology over the last decade (1–5). In TRNT a radionuclide is linked to a molecule that selectively binds to over-expressed receptors of cancer cells, allowing for a targeted approach in cancer therapy. Accumulation of the radiopharmaceutical in tumor tissue delivers toxic levels of radiation directly to the malicious tumor cells minimizing dose given to healthy tissue.

Original language	English
Article number	675221
Pages (from-to)	1-9
Number of pages	9
Journal	Frontiers in Medicine
Volume	8
DOIs	https://doi.org/10.3389/fmed.2021.675221
State	Published - 19 Jul 2021

Access to Document

10.3389/fmed.2021.675221License: Unspecified

Cite this

Van de Voorde, M., Duchemin, C., Reinhard, H., Lambert, L., Chevallay, E., Schneider, T., Van Stenis, M., Cocolios, T. E., Cardinaels, T., Ponsard, B., Ooms, M., Stora, T., & Burgoyne, A. (2021). Production of Sm-153 With Very High Speciﬁc Activity for Targeted Radionuclide Therapy. Frontiers in Medicine, 8, 1-9. Article 675221. https://doi.org/10.3389/fmed.2021.675221

@article{3e2dafd2f38e4817b1b0c3d44ce081c9,

title = "Production of Sm-153 With Very High Speciﬁc Activity for Targeted Radionuclide Therapy",

abstract = "Targeted radionuclide therapy (TRNT) has proven to be successful in oncology over the last decade (1–5). In TRNT a radionuclide is linked to a molecule that selectively binds to over-expressed receptors of cancer cells, allowing for a targeted approach in cancer therapy. Accumulation of the radiopharmaceutical in tumor tissue delivers toxic levels of radiation directly to the malicious tumor cells minimizing dose given to healthy tissue.",

keywords = "Radiolanthanides, Samarium-153, Theranostics, Targeted radionuclide therapy, Cancer, Nuclear medicine, Mass separated radionuclides, Resonant laser ionization",

author = "\{Van de Voorde\}, Michiel and Charlotte Duchemin and Heinke Reinhard and Laura Lambert and Eric Chevallay and Thomas Schneider and \{Van Stenis\}, Miranda and Cocolios, \{Thomas Elias\} and Thomas Cardinaels and Bernard Ponsard and Maarten Ooms and Thierry Stora and Andrew Burgoyne",

note = "Score=10",

year = "2021",

month = jul,

day = "19",

doi = "10.3389/fmed.2021.675221",

language = "English",

volume = "8",

pages = "1--9",

journal = "Frontiers in Medicine",

issn = "2296-858X",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Production of Sm-153 With Very High Speciﬁc Activity for Targeted Radionuclide Therapy

AU - Van de Voorde, Michiel

AU - Duchemin, Charlotte

AU - Reinhard, Heinke

AU - Lambert, Laura

AU - Chevallay, Eric

AU - Schneider, Thomas

AU - Van Stenis, Miranda

AU - Cocolios, Thomas Elias

AU - Cardinaels, Thomas

AU - Ponsard, Bernard

AU - Ooms, Maarten

AU - Stora, Thierry

AU - Burgoyne, Andrew

N1 - Score=10

PY - 2021/7/19

Y1 - 2021/7/19

N2 - Targeted radionuclide therapy (TRNT) has proven to be successful in oncology over the last decade (1–5). In TRNT a radionuclide is linked to a molecule that selectively binds to over-expressed receptors of cancer cells, allowing for a targeted approach in cancer therapy. Accumulation of the radiopharmaceutical in tumor tissue delivers toxic levels of radiation directly to the malicious tumor cells minimizing dose given to healthy tissue.

AB - Targeted radionuclide therapy (TRNT) has proven to be successful in oncology over the last decade (1–5). In TRNT a radionuclide is linked to a molecule that selectively binds to over-expressed receptors of cancer cells, allowing for a targeted approach in cancer therapy. Accumulation of the radiopharmaceutical in tumor tissue delivers toxic levels of radiation directly to the malicious tumor cells minimizing dose given to healthy tissue.

KW - Radiolanthanides

KW - Samarium-153

KW - Theranostics

KW - Targeted radionuclide therapy

KW - Cancer

KW - Nuclear medicine

KW - Mass separated radionuclides

KW - Resonant laser ionization

UR - https://ecm.sckcen.be/OTCS/llisapi.dll/open/44985253

U2 - 10.3389/fmed.2021.675221

DO - 10.3389/fmed.2021.675221

M3 - Article

SN - 2296-858X

VL - 8

SP - 1

EP - 9

JO - Frontiers in Medicine

JF - Frontiers in Medicine

M1 - 675221

ER -